Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 20, 2007

View Archived Issues

IPI-504 overcomes gefitinib resistance in non-small cell lung cancer cell lines

Velcade's significant efficacy advantage prompts early end of phase III clinical trial

FDA grants orphan drug designation to Infinity and MedImmune's IPI-504 for GIST

MicroIslet and Progenitor sign manufacturing agreement for MicroIslet-P

FDA approves five-day, once-daily regimen of Levaquin for cUTI and AP

University of Nottingham develops possible HCV vaccine

Provectus announces results of phase I metastatic melanoma study

Recent patents describe novel agents for psychiatric disorders

CP-3242: a novel metallo-beta-lactamase inhibitor profiled at the ICAAC meeting

Update on EpiCept's MAA for Ceplene in E.U.

Sosei completes phase II proof-of-principle trial of AD-337 for FMS

Novel therapeutic agents for thrombotic disorders reported in recent Trigen patent

Phase I/II clinical program to study Torisel/Velcade combination in multiple myeloma

FDA accepts Samaritan's IND for SP-6300 in Cushing's syndrome

Targeted Genetics reports results of RAC hearing on phase I/II trial of tgAAC94

Perseus and Brigham sign research agreement for cardiovascular risk predictor PTX3

MorphoSys initiates phase I trial of HuCAL gold-derived fully human antibody

Bristol-Myers begins phase II trial of p38 kinase inhibitor BMS-582949 for psoriasis

Aphios and Boston University awarded development grant for APH-M109

Phase I trial expanded after alvespimycin shows activity in metastatic breast cancer

Meta-analysis: Pioglitazone reduces ischemic cardiovascular risk in diabetes patients

mGlu2/3 receptor activation with LY-2140023 improves schizophrenia symptoms

Positive preclinical results of novel RSV fusion inhibitor TMC-353121

Triple beta-lactam combination effective in Gram-negative sepsis models

FDA grants Preos orphan drug status in hypoparathyroidism indication

E.U. grants Novo Nordisk approval for use of NovoRapid in elderly people

Smaller dose Tamiflu approved in Europe; expanded use of FluMist approved in U.S.

EMEA grants Progen's PI-88 orphan drug designation

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...